Intellia Exits Gene Editing Collaboration with Regeneron

Rare Daily Staff

In an SEC filing, Intellia Therapeutics revealed that it was opting out of a 2020 hemophilia A/B factor IX gene editing collaboration with Regeneron Pharmaceuticals.

Intellia said the factor IX co-development and co-funding agreement will terminate 180 days after Intellia provided written notice to Regeneron, and the company will continue to have obligations under the agreement related to the co-development of gene editing products directed to factor IX until the effective date of termination, which time it will no longer be obligated for sharing 35 percent of the development costs, or be entitled to receive 35 percent of the profits, for gene editing products directed to factor IX under the agreement.

In addition, after termination of the co-development and co-funding agreement, Intellia will continue to support Regeneron with the development of gene editing products directed to factor IX, as applicable, under their license and collaboration agreement signed in April 2016, which will control the parties’ obligations to develop and commercialize gene editing products directed to factor IX, including any milestone payments and royalties that would be owed to the company if Regeneron develops and commercializes such products and the intellectual property licenses and other rights related to such products.

Under the license and collaboration agreement, Intellia may be eligible to receive up to $320.0 million in milestone payments, and royalties in the high-single digits to low teens.